308 related articles for article (PubMed ID: 34080787)
1. Vitamin D and Vitamin D-binding protein and risk of bladder cancer: A nested case-control study in the Norwegian Janus Serum Bank Cohort.
Hektoen HH; Robsahm TE; Stenehjem JS; Axcrona K; Babigumira R; Mondul AM; Gislefoss RE; Andreassen BK
Cancer Med; 2021 Jun; 10(12):4107-4116. PubMed ID: 34080787
[TBL] [Abstract][Full Text] [Related]
2. Influence of vitamin D binding protein on the association between circulating vitamin D and risk of bladder cancer.
Mondul AM; Weinstein SJ; Virtamo J; Albanes D
Br J Cancer; 2012 Oct; 107(9):1589-94. PubMed ID: 22990651
[TBL] [Abstract][Full Text] [Related]
3. Serum vitamin D, vitamin D binding protein, and lung cancer survival.
Anic GM; Weinstein SJ; Mondul AM; Männistö S; Albanes D
Lung Cancer; 2014 Dec; 86(3):297-303. PubMed ID: 25456734
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D-binding protein, circulating vitamin D and risk of renal cell carcinoma.
Mondul AM; Weinstein SJ; Moy KA; Männistö S; Albanes D
Int J Cancer; 2014 Jun; 134(11):2699-706. PubMed ID: 24214881
[TBL] [Abstract][Full Text] [Related]
5. Serum vitamin D, vitamin D binding protein, and risk of colorectal cancer.
Anic GM; Weinstein SJ; Mondul AM; Männistö S; Albanes D
PLoS One; 2014; 9(7):e102966. PubMed ID: 25036524
[TBL] [Abstract][Full Text] [Related]
6. Serum vitamin D and risk of bladder cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening trial.
Mondul AM; Weinstein SJ; Horst RL; Purdue M; Albanes D
Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1222-5. PubMed ID: 22623707
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D-binding protein and pancreatic cancer: a nested case-control study.
Piper MR; Freedman DM; Robien K; Kopp W; Rager H; Horst RL; Stolzenberg-Solomon RZ
Am J Clin Nutr; 2015 Jun; 101(6):1206-15. PubMed ID: 25904602
[TBL] [Abstract][Full Text] [Related]
8. Impact of circulating vitamin D binding protein levels on the association between 25-hydroxyvitamin D and pancreatic cancer risk: a nested case-control study.
Weinstein SJ; Stolzenberg-Solomon RZ; Kopp W; Rager H; Virtamo J; Albanes D
Cancer Res; 2012 Mar; 72(5):1190-8. PubMed ID: 22232734
[TBL] [Abstract][Full Text] [Related]
9. Prediagnostic Serum 25-Hydroxyvitamin D and Mortality Among Bladder Cancer Patients in the Janus Serum Bank Cohort.
Hektoen HH; Gislefoss RE; Stenehjem JS; Langseth H; Axcrona K; Mondul AM; Robsahm TE; Andreassen BK
Clin Epidemiol; 2021; 13():801-811. PubMed ID: 34548821
[TBL] [Abstract][Full Text] [Related]
10. Lifestyle associated factors and risk of urinary bladder cancer: A prospective cohort study from Norway.
Hektoen HH; Robsahm TE; Andreassen BK; Stenehjem JS; Axcrona K; Mondul A; Gislefoss RE
Cancer Med; 2020 Jun; 9(12):4420-4432. PubMed ID: 32319230
[TBL] [Abstract][Full Text] [Related]
11. Serum 25-hydroxyvitamin D, vitamin D binding protein and risk of colorectal cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Weinstein SJ; Purdue MP; Smith-Warner SA; Mondul AM; Black A; Ahn J; Huang WY; Horst RL; Kopp W; Rager H; Ziegler RG; Albanes D
Int J Cancer; 2015 Mar; 136(6):E654-64. PubMed ID: 25156182
[TBL] [Abstract][Full Text] [Related]
12. Serum 25-hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men.
Layne TM; Weinstein SJ; Graubard BI; Ma X; Mayne ST; Albanes D
Cancer; 2017 Jul; 123(14):2698-2704. PubMed ID: 28369777
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D, obesity and leptin in relation to bladder cancer incidence and survival: prospective protocol study.
Gislefoss RE; Stenehjem JS; Hektoen HH; Andreassen BK; Langseth H; Axcrona K; Weiderpass E; Mondul A; Robsahm TE
BMJ Open; 2018 Mar; 8(3):e019309. PubMed ID: 29602840
[TBL] [Abstract][Full Text] [Related]
14. Association of thyroid cancer risk with plasma 25-hydroxyvitamin D and vitamin D binding protein: a case-control study in China.
Hu MJ; Niu QS; Wu HB; Lu XL; Wang L; Tong XR; Huang F
J Endocrinol Invest; 2020 Jun; 43(6):799-808. PubMed ID: 31863361
[TBL] [Abstract][Full Text] [Related]
15. Circulating 25-hydroxyvitamin D, vitamin D-binding protein and risk of prostate cancer.
Weinstein SJ; Mondul AM; Kopp W; Rager H; Virtamo J; Albanes D
Int J Cancer; 2013 Jun; 132(12):2940-7. PubMed ID: 23180681
[TBL] [Abstract][Full Text] [Related]
16. Association of serum 25-hydroxy-vitamin D concentration and risk of mortality in cancer survivors in the United States.
Mo X; He C; Han F; Yan H; Chen X; Wang Y; Zhou M
BMC Cancer; 2024 Apr; 24(1):545. PubMed ID: 38689243
[TBL] [Abstract][Full Text] [Related]
17. Prediagnostic serum 25-hydroxyvitamin D and melanoma risk.
Stenehjem JS; Støer NC; Ghiasvand R; Grimsrud TK; Babigumira R; Rees JR; Nilsen LT; Johnsen B; Thorsby PM; Veierød MB; Robsahm TE
Sci Rep; 2020 Nov; 10(1):20129. PubMed ID: 33208828
[TBL] [Abstract][Full Text] [Related]
18. In healthy adults, biological activity of vitamin D, as assessed by serum PTH, is largely independent of DBP concentrations.
Dastani Z; Berger C; Langsetmo L; Fu L; Wong BY; Malik S; Goltzman D; Cole DE; Richards JB
J Bone Miner Res; 2014 Feb; 29(2):494-9. PubMed ID: 23857798
[TBL] [Abstract][Full Text] [Related]
19. Bioavailable and free 25-hydroxyvitamin D and vitamin D binding protein in polycystic ovary syndrome: Relationships with obesity and insulin resistance.
Naderpoor N; Shorakae S; Abell SK; Mousa A; Joham AE; Moran LJ; Stepto NK; Spritzer PM; Teede HJ; de Courten B
J Steroid Biochem Mol Biol; 2018 Mar; 177():209-215. PubMed ID: 28734987
[TBL] [Abstract][Full Text] [Related]
20. Maternal and Newborn Vitamin D-Binding Protein, Vitamin D Levels, Vitamin D Receptor Genotype, and Childhood Type 1 Diabetes.
Tapia G; Mårild K; Dahl SR; Lund-Blix NA; Viken MK; Lie BA; Njølstad PR; Joner G; Skrivarhaug T; Cohen AS; Størdal K; Stene LC
Diabetes Care; 2019 Apr; 42(4):553-559. PubMed ID: 30692241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
